Helen J. Gogas
Experienced in Metastatic Brain Tumor

Helen J. Gogas

80 Vasilisis Sofias Avenue, 
Athens, ESYE31, GR 
Experienced in Metastatic Brain Tumor
80 Vasilisis Sofias Avenue, 
Athens, ESYE31, GR 
OverviewLocationsClinical Research

Overview

Helen Gogas practices in Athens, Greece. Ms. Gogas is rated as an Experienced expert by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Melanoma, Breast Cancer, Febrile Neutropenia, Multifocal Atrial Tachycardia, and Small Bowel Resection.

Her clinical research consists of co-authoring 261 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Metastatic Brain Tumor.

Gender
Female

Locations

80 Vasilisis Sofias Avenue, Athens, ESYE31, Greece
Other Locations
80 Vasilissis Sofias Av. And Lourou Str, Athens, ESYE31 11528, Greece

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drugs: LGX818, MEK162, Nivolumab, Ipilimumab
Study Phase: Phase 2

261 Total Publications

Real-world safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive/HER2-low metastatic breast cancer: a multicenter retrospective cohort study.
Real-world safety and efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive/HER2-low metastatic breast cancer: a multicenter retrospective cohort study.
Journal: Future oncology (London, England)
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Gogas's expertise for a condition
ConditionClose
View All 30 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile